Type Public Industry Health care Founded 2001 | Traded as NYSE: GKOS Revenue 45.6 million USD (2014) | |
 | ||
Founder Olav Bergheim
Richard Hill
Mory Gharib Key people Thomas Burns (President and CEO) Stock price GKOS (NYSE) US$ 44.68 -0.34 (-0.76%)14 Mar, 1:01 PM GMT-4 - Disclaimer Headquarters San Clemente, California, United States Net income 14.1 million USD (loss, 2014) | ||
Introducing the istent from glaukos corporation
Glaukos Corporation is a glaucoma treatment company based in Laguna Hills, California. Thomas Burns is Glaukos' president and CEO.
Contents
- Introducing the istent from glaukos corporation
- Company presentations glaukos
- Products
- Business model
- History
- References
Company presentations glaukos
Products
Glaukos developed the "iStent" titanium micro-stent. The device, which is about the width of a human hair, is implanted during cataract surgery to reduce intraocular pressure. As of 2015, the iStent was the smallest device ever approved by the United States Food and Drug Administration. The availability of the iStent led to the addition of two codes to the Current Procedural Terminology set in 2015, 0191T and 0376T.
Business model
In 2015, Glaukos planned to transition from private company status to become a public company with an initial public offering (IPO) of company stock. The proposed stock symbol for the company was "GKOS".
Glaukos' president and chief executive officer (CEO) Thomas Burns says Glaukos was the first to develop micro-stents for the treatment of glaucoma and is well ahead of its competitors. The CEO of MicroOptx, Chris Pulling, has stated that Glaukos is his "most direct" competitor.
History
Founded in 2001 by Olav Bergheim, Richard Hill and Mory Gharib, the company has raised $156 million in venture funding from Versant Ventures, OrbiMed Advisors, Frazier Healthcare Ventures, InterWest Partners, Meritech Capital Partners, Domain Associates, Fjord Capital Management and Montreux Equity Partners.
The company ranked 19th on the Wall Street Journal's annual Next Big Thing list in 2011.
The company ranked seventh on the Wall Street Journal's annual Next Big Thing list in 2012.
In June 2012, the Food and Drug Administration approved the first iStent implant.